MAR.F MARAVAI LIFESC.HLD.A -01
- Market cap
- EUR 1.78B
- P/E
- -
- P/B
- 5.91x
- ROE
- -20.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MAR.F undervalued?
Graham numberThe Graham number of MARAVAI LIFESC.HLD.A -01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MARAVAI LIFESC.HLD.A -01 fundamental analysis
No fundamental analysis for MARAVAI LIFESC.HLD.A -01 yet.
MARAVAI LIFESC.HLD.A -01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MARAVAI LIFESC.HLD.A -01
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonu…
Full company profileMARAVAI LIFESC.HLD.A -01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MARAVAI LIFESC.HLD.A -01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 799M | 883M | 289M | 259M | 186M | 218M |
| Gross Profit | 659M | 714M | 140M | 108M | 34.0M | 94.1M |
| Operating Income | 543M | 566M | -28.5M | -72.7M | -129M | -42.8M |
| EBITDA | - | 610M | 712M | -157M | -148M | 3.22M |
| Net Income | 182M | 220M | -119M | -145M | -131M | -40.0M |
| EPS | 1.38 | 1.67 | -0.90 | -1.02 | -0.90 | -0.27 |
| Balance Sheet | ||||||
| Total Assets | 1.92B | 2.28B | 1.49B | 1.01B | 771M | 600M |
| Total Liabilities | 1.37B | 1.38B | 698M | 431M | 398M | 260M |
| Shareholders' Equity | 315M | 545M | 417M | 325M | 212M | 196M |
| Cash & Short-term Investments | 551M | 632M | 575M | 322M | 217M | 73.0M |
| Cash Flow | ||||||
| Operating Cash Flow | 369M | 536M | 126M | 7.47M | -57.6M | 23.6M |
| Capital Expenditure | 14.9M | 17.1M | 65.6M | 31.2M | 13.1M | 7.11M |
| Free Cash Flow | 354M | 519M | 60.7M | -23.7M | -70.7M | 16.5M |
| Ratios | ||||||
| ROE | 57.7% | 40.4% | -28.6% | -44.5% | -61.6% | -20.4% |
| ROA | 9.5% | 9.6% | -8.0% | -14.4% | -17.0% | -6.7% |
| Net Profit Margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% | -18.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MARAVAI LIFESC.HLD.A -01 dividends
MARAVAI LIFESC.HLD.A -01 has not paid dividends in the last 5 fiscal years.
Who owns MARAVAI LIFESC.HLD.A -01
- Insiders 7.21%
- Institutions 92.79%
- Public & others 0.00%
- Shares outstanding 149M
- Free float 107M
MARAVAI LIFESC.HLD.A -01 company profile
- Company name
- MARAVAI LIFESC.HLD.A -01
- Ticker
- MAR.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 410
- Fiscal year end
- December
- Address
- 10770 Wateridge Circle, San Diego, CA, United States, 92121
- Phone
- 858 546 0004
- Website
- maravai.com
About MARAVAI LIFESC.HLD.A -01
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
MARAVAI LIFESC.HLD.A -01 management
10- Mr. Robert Andrew Eckert M.B.A.Chairman of the Board · born 1962
- Mr. Bernd BrustCEO & Director · born 1967
- Mr. Rajesh J. AsorpotaEVP & Chief Financial Officer · born 1967
- Mr. Kurt A. Oreshack J.D.Executive VP, General Counsel & Secretary · born 1981
- Ms. Christine DolanExecutive VP & GM of Cygnus Technologies · born 1968
- Ms. Chanfeng ZhaoSenior VP & Chief Scientific Officer
- Ms. Debra HartSenior Director of Investor Relations
- Ms. Judith A. SoleckiSenior VP & Chief Human Resources Officer
- Dr. Kate E. Broderick Ph.D.Executive Vice President
- Mr. Christopher C. BenoitExecutive VP & Advisor